ArticleFrontiers in pharmacology2021
Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Pooled it
- C-X-C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8International journal of cancer · 2026Article
- Emodin: A Promising Natural Compound for Combating Fibrotic Diseases.Current medical science · 2026Review
- Cardiovascular burden of long coronavirus disease: Clinical challenges and emerging biomarkers.World journal of cardiology · 2026Review
- Kidney Fibrosis In Vitro and In Vivo Models: Path Toward Physiologically Relevant Humanized Models.Advanced healthcare materials · 2025Review
- Neonatal hyperoxia exposure leads to developmental programming of cardiovascular and renal disease in adult rats.Scientific reports · 2024Article
- Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis.Biomarker research · 2024Article
- Article
- Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era.Frontiers in microbiology · 2024Review
- Tanshinone I attenuates fibrosis in fibrotic kidneys through down-regulation of inhibin beta-A.BMC complementary medicine and therapies · 2022Article
- Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19.Pharmacology research & perspectives · 2022Review
- Remdesivir for COVID-19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature.Clinical case reports · 2022Article
- Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.Topics in current chemistry (Cham) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.